Common Variants of the Prostaglandin-Endoperoxide Synthase 2 Gene and Hepatocellular Carcinoma Susceptibility. Issue 35 (September 2015)

• Record Type: Journal Article
• Authors: Li, Hong-guang; Liu, Fang-feng; Zhu, Hua-qiang; Zhou, Xu; Lu, Jun; Chang, Hong; Hu, Jin-hua; Gilbert, Fruhwirth.
• Is Part Of: Medicine. Volume 94:Issue 35(2015)
• Publication Date: 2015-09
• Subjects: Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000001116
• Languages: English
• ISSNs: 0025-7974

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <title>Abstract</title> <p>Hepatocellular carcinoma (HCC) is a heterogeneous disease with substantial genetic constitution. Previous work has evaluated the effect of prostaglandin-endoperoxide synthase 2 (<italic>PTGS2</italic>) variants (−765G/C, −1195A/G, and +8473T/C) on the development of HCC, but the conclusions are inconsistent. We conducted a meta-analysis in this work. Data from 7 case–control studies were combined to assess the association between <italic>PTGS2</italic> variants and HCC. The risk of HCC (OR and 95% CI) was estimated using either the fixed- or the random-effects model according to the Q test. No significant association was identified for −765G/C and +8473T/C. However, we identified a significantly decreased risk in relation to the GG genotype of −1195A/G (OR = 0.70, 95% CI = 0.50–0.98 for GG versus AA). We also observed a similar decrease (OR = 0.47, 95% CI = 0.23–0.95 for GG versus AA) in Caucasian samples. Variant −1195A/G in the promoter <italic>PTGS2</italic> may protect against the malignant progression of HCC. This significant association suggests that −1195A/G could be used as a biomarker of HCC.</p> </sec> </abstract>